Persistence: 143.6 days (Trulicity) versus 129.9 days (semaglutide). Treatment discontinuation: 30.8 percent (Trulicity) versus 40.8 percent (
If a hypersensitivity reaction occurs, discontinue use of TRULICITY and other suspect medications and promptly seek medical advice. TRULICITY
patients on other Trulicity doses were discontinued. In addition to those assigned to Trulicity in the dose-finding period, immediately following the lead
Persistence: 142 days (Trulicity) versus 121.4 days (exenatide). Treatment discontinuation: 32.1 percent (Trulicity) versus 49.4 percent (
Further, significantly fewer people discontinued treatment with Trulicity compared to semaglutide or exenatide.1. Trulicity versus injectable
Trulicity may increase the risk of pancreatitis. If this occurs, Trulicity should be discontinued and not restarted. There have also been
TRULICITY. If a hypersensitivity reaction occurs, discontinue TRULICITY; treat promptly per standard of care, and monitor until signs and
Trulicity may increase the risk of pancreatitis. If this occurs, Trulicity should be discontinued and not restarted. There have also been
If a hypersensitivity reaction occurs, discontinue TRULICITY; treat promptly per standard of care, and monitor until signs and symptoms resolve. TRULICITY is.
Comments